What question did this study set out to answer?

To evaluate the efficacy of PDA@CeMn nanozyme in protecting the myocardium through ROS scavenging and inflammation suppression.

June 12, 2026Open Access

PDA@CeMn nanozyme for enhanced myocardial protection via ROS scavenging and inflammation suppression

Key Points

To evaluate the efficacy of PDA@CeMn nanozyme in protecting the myocardium through ROS scavenging and inflammation suppression.
Utilized PDA@CeMn nanozyme with enzyme-like activity for treatment.
Evaluated effects on reactive oxygen species and inflammatory pathways in myocardial tissues.
Assessed outcomes related to cardiac function and myocardial health.
Demonstrated significant reduction in reactive oxygen species levels post-treatment.
Notable decrease in inflammation markers within myocardial tissues detected post-intervention.
Improved cardiac function metrics observed in treatment groups.

Abstract

Abstract The mortality rate of cardiovascular diseases (CVD) remains alarmingly high. Studies have shown that reactive oxygen species (ROS)-mediated inflammatory responses and oxidative stress are key pathological mechanisms driving CVD. Nanozymes, nanomaterials with enzyme-like activities, offer several advantages over natural enzymes, including enhanced stability and scalability. Previous research has demonstrated that nanozymes containing cerium (Ce) or manganese (Mn) possess excellent ROS-scavenging capabilities. Dopamine, a positive inotropic agent commonly used in clinical practice to improve cardiac function in patients with heart failure, has also been shown to self.

Bookmark

View Full Paper

Cite This Study

Zhou et al. (Wed,) studied this question.

synapsesocial.com/papers/6a2ba31a8101cf8926f01ecf https://doi.org/https://doi.org/10.1038/s41427-026-00662-7

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper